This is a routine insider sale by a director, likely for personal portfolio management. No material signal for the stock. Monitor for any larger insider sales or changes in insider selling patterns.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $961.26entry
- T+1 · 14d ago +1.26%α +0.96% · $973.36
- T+5 · 8d ago −4.30%α −4.37% · $919.96
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Kathryn Guarini filed a Form 144 notice of intent to sell 400 shares of Regeneron common stock, valued at approximately $360,000 based on the filing price. The shares were acquired through option exercise and the sale is a routine, small disposition relative to the director's total holdings and the company's $83.7B market cap.
Key Facts
- Director Kathryn Guarini filed Form 144 to sell 400 shares of Regeneron common stock.
- Estimated value of the proposed sale is $360,000.
- Shares were acquired via exercise of stock options on October 30, 2026.
- The sale is a small fraction of the director's total holdings (101,630,713 shares outstanding).
- The filing represents only an intent to sell; the transaction may not be completed.
Financial Impact
Proceeds of approximately $360,000, representing less than 0.0004% of Regeneron's $83.7B market cap.
Risk Factors
- Form 144 is only an intent to sell; the sale may not occur.
- Insider selling can sometimes precede negative news, but the small size here makes that unlikely.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001109 |
| Document: 0001969223-26-001109-index.html | 0001969223-26-001109 |
| Document: 0001969223-26-001109.txt | 0001969223-26-001109 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers